Arsenic trioxide
- Generic Name
- Arsenic trioxide
- Brand Names
- Trisenox, Arsenic trioxide Accord, Arsenic trioxide Mylan, Arsenic trioxide medac
- Drug Type
- Small Molecule
- Chemical Formula
- As2O3
- CAS Number
- 1327-53-3
- Unique Ingredient Identifier
- S7V92P67HO
- Background
Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.
- Indication
For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
- Associated Conditions
- Acute Promyelocytic Leukemia, Refractory Acute Promyelocytic Leukemia, Relapsed Acute Promyelocytic Leukemia
Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma
- Conditions
- Neuroblastoma
- Interventions
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-04-18
- Target Recruit Count
- 92
- Registration Number
- NCT06933394
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)
- Conditions
- Low-risk Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 24
- Registration Number
- NCT06670222
- Locations
- 🇫🇷
CHU de Nice - Hôpital l'Archet - Service d'hématologie clinique, Nice, France
🇫🇷Hôpital Saint Louis - Service Hématologie séniors, Paris, France
🇫🇷Institut Gustave Roussy - Service d'hématologie, Villejuif, France
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
- Conditions
- Li-Fraumeni Syndromep53 MutationsPediatric Cancer
- Interventions
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Yang Li
- Target Recruit Count
- 50
- Registration Number
- NCT06088030
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL
- Conditions
- Promyelocytic Leukemia
- Interventions
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Target Recruit Count
- 15
- Registration Number
- NCT05497310
- Locations
- 🇲🇽
Hopsital Universitario Dr. Jose E. Gonzalez, Centro Universitario contra el Cancer, Monterrey, Nuevo Leon, Mexico
Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2022-03-28
- Target Recruit Count
- 30
- Registration Number
- NCT05297123
- Locations
- 🇨🇳
First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
- Conditions
- Acute Promyelocytic Leukemia
- Interventions
- Drug: SY-2101
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Syros Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT04996030
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04869475
- Locations
- 🇨🇳
Department of Oncology, Ruijin Hospital, Shanghai, China
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
- Conditions
- Acute Promyelocytic Leukemia
- Interventions
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Associazione Italiana Ematologia Oncologia Pediatrica
- Target Recruit Count
- 89
- Registration Number
- NCT04793919
- Locations
- 🇵🇹
Instituto Português de Oncologia do Porto Francisco Gentil, E. P. E., Porto, Portugal
🇮🇹AOU Policlinico Dipartimento di Pediatria, Bari, Italy
🇮🇹Ospedale Papa Giovanni XXIII - USS Oncoematologia Pediatrica, Bergamo, Italy
Use of Topical Solasodine of Solanum Melongena Peel Origin in the Treatment of Palmar Arsenic Keratosis
- Conditions
- Keratotic Nodular Size
- Interventions
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Target Recruit Count
- 20
- Registration Number
- NCT04693000
- Locations
- 🇧🇩
Muradnagar Upazilla, Comilla, Bangladesh
Arsenic Trioxide for Structural p53 Mutations
- Conditions
- Refractory Cancerp53 MutationsIntractable CancerArsenic Trioxide
- Interventions
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04695223
- Locations
- 🇨🇳
Department of Medical Oncology, Shanghai Changzheng Hospital, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.